Downregulation of snoRNA SNORA52 and Its Clinical Significance in Hepatocellular Carcinoma

Table 2

Univariate and multivariate analysis of disease-free survival in HCC patients.

Clinicopathologic parameters	Univariate analysis		Multivariate analysis
	HR (95% CI)		HR (95% CI)
Age (<60 vs. ≥60)	0.637 (0.371-1.093)	0.102
Gender (female vs. male)	1.506 (0.647-3.506)	0.342
Hepatitis B (negative vs. positive)	1.729 (0.785-3.810)	0.174
AFP (<400 vs. ≥400)	1.355 (0.808-2.273)	0.249
Cirrhosis (present vs. absent)	1.302 (0.764-2.221)	0.332
Microvascular invasion (present vs. absent)	0.931 (0.337-2.573)	0.891
Tumor differentiation (low vs. high/moderate)	1.018 (0.611-1.698)	0.944
Capsular invasion (present vs. absent)	1.575 (0.939-2.644)	0.085	1.272 (0.753-2.147)	0.369
TNM stage (I~II vs. III~IV)	2.008 (1.190-3.386)	0.009	1.094 (0.550-2.175)	0.798
Tumor diameter (<5 cm vs. ≥5 cm)	1.875 (1.010-3.482)	0.046	1.861 (0.969-3.571)	0.062
Multiple lesions (present vs. absent)	2.481 (1.392-4.419)	0.002	2.229 (1.245-3.993)	0.007
Vessel carcinoma embolus (present vs. absent)	2.250 (1.260-4.019)	0.006	2.195 (1.169-4.120)	0.014
SNORA52 expression (low vs. high)	0.374 (0.220-0.634)	<0.001	0.481 (0.277-0.836)	0.009

AFP: α-fetoprotein; TNM: tumor-node-metastasis; was considered to be statistically significant.